MedElevator
Войти в исследования Tracking Clostridioides difficile in Germany: Active prospective surveillance progress and molecular epidemiological trends.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdrabou Ahmed Mostafa, Schneider Julia S, Berger Fabian K, Bischoff Markus, Müller Lutz von, Mellmann Alexander, Gärtner Barbara C, German C. difficile surveillance group, Hoffmann Reinhard, Simon Valeska, Büchler Christian, Schaumburg Frieder, Schoeler Sarah, Hagemann Jürgen Benjamin, Wolffhardt Tatjana Magdalena, Bohne Wolfgang, Groß Uwe, Ulm Lena, Becker Karsten, Hogardt Michael, Burbach Tobias, Dziobaka Jan, Buer Jan, Pauly Sebastian, Zautner Andreas E, Kaasch Achim J, Badr Mohamed Tarek, Forster Johannes, Lâm Thiên-Trí, Gerigk Marlis, Trimborn Anna, Hamprecht Axel, Hellkamp Josef, Friedrich Christine, Papadopoulou Despina, Jung Jette, Weikert-Asbeck Simone, Maschkowitz Gregor, Neumayr Veronika, Häcker Georg, Institut für Medizinische Laboratoriumsdiagnostik (IML), GmbH Bochum, Schmiedel Judith, Fritzenwanker Moritz, Sägmüller Josef, Laboratories Duesseldorf Medical, Haase Gerhard, Haefner Helga, Stingu Catalina-Suzana, Dietze-Jergus Nadine, Wolf Sophia, Schmidt Annika, Institute of Medical Microbiology and Virology, University Hospital Carl Gustav Carus, Dresden Technische Universität, Hospital Düsseldorf University, Burbach Tobias, Hogardt Michael
Аннотация
METHODS: As active surveillance, the first 10 stool samples tested positive for toxigenic C. difficile (one per patient) were collected biannually from 33 German microbiological laboratories. Passive surveillance included samples from severe cases and outbreaks. Isolates underwent genotypic characterization and antimicrobial susceptibility testing.
RESULTS: Regarding active surveillance, 1257 toxigenic C. difficile isolates were retrieved between October 2021 to October 2023. Previous surveillance data (n = 876) were added dating back to 2019. Among the 2133 strains, RT014 (18%), RT078 (7%) and RT001 (6%) were the most common RTs, while RT027 declined between 2019 and 2023 from 5% to 0.6%. Concerning the passive surveillance, from 509 isolates, RT027 was most prevalent (16%), followed by RT014 (13%), RT001 and RT002 (6% each). Emerging RTs, namely RT181 and RT955, were rarely detected or absent, respectively. No resistance to vancomycin or fidaxomicin was detected, and metronidazole resistance was low (0.5%). C. difficile RT027 isolates displayed high resistance for moxifloxacin, clarithromycin and rifampicin (~95%, ~95% and~70%, respectively). During the COVID-19 pandemic, no significant trends in RT diversity were observed while the reported number of cases decreased.
CONCLUSION: RT014 continues to be the most prevalent RT. Hypervirulent RTs remained rather constant, although numbers of RT027 declined over time. Ongoing surveillance remains crucial for monitoring emergent RTs.